Zogenix Buys Modis in $400 Million-Plus Deal to Make Larger Rare Disease Company BioSpace
This transaction advances Zogenix’s mission to become a leading rare disease pharmaceutical company by adding MT1621 to our pipeline of late-stage …
Zogenix Buys Modis in $400 Million-Plus Deal to Make Larger Rare Disease Company BioSpace
This transaction advances Zogenix’s mission to become a leading rare disease pharmaceutical company by adding MT1621 to our pipeline of late-stage …